ReviewScientific reports2016

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.

Jianlin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.